Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 3 of 6 for:    Creutzfeldt-Jakob Disease

The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
University of Utah
ClinicalTrials.gov Identifier:
NCT00721864
First received: July 23, 2008
Last updated: August 5, 2011
Last verified: August 2011
  Purpose

This study is designed to better understand the molecular biology of paroxysmal nocturnal hemoglobinuria (PNH) and to determine if prion protein (PrP) functions in long term hematopoietic stem cell renewal.


Condition
Hemoglobinuria, Paroxysmal

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Resource links provided by NLM:


Further study details as provided by University of Utah:

Primary Outcome Measures:
  • Identify the mutation causing the predominant clones through analysis of extracted DNA/RNA from erythroid colonies [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reconfirmation of PrP expression in human granulocytes, hematopoietic progenitors and stem cells [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]
  • Analysis of PrP function in human long term hematopoietic stem cells [ Time Frame: After sample is obtained ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole Blood


Enrollment: 10
Study Start Date: May 2006
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Affected Population
Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)

Detailed Description:

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolytic anemia, thrombosis, and variable cytopenia. It can be associated with significant morbidity including acute kidney failure, cerebral infarction, mesenteric infarction, Budd-Chiari syndrome, aplastic anemia, and leukemic transformation. The average survival time from diagnosis is 15 years.

PNH is an acquired clonal disorder of the hematopoietic stem cell. Two distinct populations of hematopoietic cells exist in each PNH patient: one non-clonal population of normal cells, and one clonal population of PNH cells. The clonal population of PNH cells is identified by a mutation in the PIG-A gene that results in absence of the glycophosphatidylinositol (GPI) anchor of several surface proteins. Consequently, these surface proteins are unable to perform their functions on the cell surface. Deficiency of two of these surface proteins, CD55 (decay accelerating factor) and CD59 (membrane inhibitor of reactive lysis) that prevent complement mediated destruction, have been shown to underlie the clinical presentation of PNH. Identifying the mutation causing the predominant clones may help us better understand the molecular biology of PNH. When this is accomplished, new therapies to control and eventually cure the disease can be designed.

In addition, we propose to determine the function of PrP in human hematopoietic stem cells. PrP is a glycoprotein attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. In PNH, a disorder whose pathogenesis lies in the absence of GPI anchors, PrP expression is reduced in monocytes and granulocytes from the PNH clone.

  Eligibility

Ages Eligible for Study:   7 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with paroxysmal nocturnal hemoglobinuria (PNH)

Criteria

Inclusion Criteria:

  1. Subjects suspected of or diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH)
  2. Age > 7

Exclusion Criteria:

1. Those not meeting the inclusion criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00721864

Locations
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
University of Utah
Investigators
Principal Investigator: Josef T Prchal, MD University of Utah
  More Information

Publications:
Responsible Party: Josef T. Prchal, MD, University of Utah
ClinicalTrials.gov Identifier: NCT00721864     History of Changes
Other Study ID Numbers: 17790, R01HL5077-12
Study First Received: July 23, 2008
Last Updated: August 5, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Utah:
Paroxysmal Nocturnal Hemoglobinuria
PIG-A Mutation
Prion Protein
Hematopoietic stem cells
Clonal disorder

Additional relevant MeSH terms:
Bone Marrow Diseases
Hematologic Diseases
Urination Disorders
Urologic Diseases
Hemoglobinuria
Hemoglobinuria, Paroxysmal
Anemia
Anemia, Hemolytic
Myelodysplastic Syndromes
Proteinuria
Signs and Symptoms
Urological Manifestations

ClinicalTrials.gov processed this record on November 24, 2014